An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia-Reference-Cited by-同舟云学术

An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia

Published:2020-10 Issue: Volume:29 Page:102283
ISSN:1549-9634
Container-title:Nanomedicine: Nanotechnology, Biology and Medicine
language:en
Short-container-title:Nanomedicine: Nanotechnology, Biology and Medicine

Author:

Fu Liyi,Zou Fengming,Liu Qingwang,Wang Beilei,Wang Junqing,Liang Huamin,Liang Xiaofei,Liu Jing,Shi Jinjun,Liu Qingsong

Funder

Strategic Priority Research Program of the Chinese Academy of Sciences

Natural Science Foundation of Anhui Province

Frontier Science Key Research Program of CAS

CASHIPS Director's Fund

Key Program of 13th five-year plan of CASHIPS

Hefei leading talent

Youth Innovation Promotion Association

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Materials Science,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering

Reference42 articles.

1. Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China;Li;Clin Drug Investig,2018

2. Mechanisms of disease—the biology of chronic myeloid leukemia;Faderl;N Engl J Med,1999

3. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

4. Mechanisms of disease-chronic myeloid leukemia-advances in biology and new approaches to treatment;Goldman;N Engl J Med,2003

5. Delicious poison: arsenic trioxide for the treatment of leukemia;Kwong;Blood,1997

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia;ADMET and DMPK;2023-09-26

2. PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML);Pharmaceutics;2022-08-10